Addition of Dr. Chi brings Bovie’s MAB to five members, who will advance the adoption of J-Plasma® in new and existing specialties.

CLEARWATER, FL – January 24, 2017 – 
Bovie Medical Corporation (“Bovie” or the “Company”) (NYSE: BVX), a maker of medical devices and supplies and the developer of J-Plasma®, a patented new surgical product, announced today the appointment of Dr. Dennis S. Chi, a renowned gynecologic oncology surgeon, to its Medical Advisory Board.

As Deputy Chief and Head of Ovarian Cancer Surgery at Memorial Sloan Kettering Cancer Center, Dr. Chi specializes in using the most advanced minimally invasive surgical techniques to treat cervical, uterine and ovarian cancer and has received numerous accolades over his 20-year career.

“Advanced energy technologies such as J-Plasma® hold the promise of improving outcomes and reducing discomfort and recuperative time for patients. As an advocate for minimally invasive surgical techniques and new treatment options for gynecologic oncology, I am delighted to join Bovie’s Medical Advisory Board,” Dr. Chi said.

“Dr. Chi’s clinical expertise will be of significant benefit as J-Plasma’s adoption continues to gain momentum, both within existing specialties and across new markets. His appointment reinforces the enthusiasm top surgeons have for J-Plasma’s potential and the caliber of our Medical Advisory Board,” Robert L. Gershon, Chief Executive Officer of Bovie Medical said.

Dr. Chi has been the principal investigator of several institutional and multi-center trials, and has published more than 100 papers on ovarian cancer surgery. The addition of Dr. Chi brings Bovie Medical’s MAB board to five members, representing specialties which include urology, obstetrics, cardiac surgery, thoracic surgery, and gynecologic oncology. The MAB has several clinical studies planned for 2017 to demonstrate the advantages of J-Plasma® in specific clinical applications.

About Bovie Medical Corporation

Bovie Medical Corporation is a leading maker of medical devices and supplies as well as the developer of J-Plasma®, a patented new plasma-based surgical product for cutting and coagulation. J-Plasma® utilizes a helium ionization process to produce a stable, focused beam of ionized gas that provides surgeons with greater precision, minimal invasiveness and an absence of conductive currents through the patient during surgery. Bovie Medical Corporation is also a leader in the manufacture of a range of electrosurgical products and technologies, marketed through both private labels and the Company’s own well-respected brands (Bovie®, Aaron®, IDS™ and ICON™) to distributors worldwide. The Company also leverages its expertise through original equipment manufacturing (OEM) agreements with other medical device manufacturers. For further information about the Company’s current and new products, please refer to the Investor Relations section of Bovie Medical Corporation’s website

Investor Relations:

Bovie Medical Corporation
MBS Value Partners
Lynn Morgen/ Jane Searle
212 750 5800